The main risk is economic conversion, not reactor science. NuScale has a rare licensing asset, strong liquidity, and improving supplier readiness, but shareholder value only scales if partner-led projects become binding, financeable, and executable before
dilution, timing slippage, or rival pathways erode the advantage.